Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01866709 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of Sodium Polystyrene Sulfonate in Hyperkalemia
A Phase 4 study, sponsored by ZS Pharma.
- Terminated
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
NCT01866709 is a Phase 4 study that was terminated before completion, run by ZS Pharma. The registered enrollment target is 32 participants.
The verdict
NCT01866709, a Phase 4 study, was terminated before completion, sponsored by ZS Pharma.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
Study Summary
It is hypothesized that SPS is more effective than placebo control (alternative hypothesis) in lowering i-STAT potassium levels in subjects with i-STAT potassium levels between 5.0 - 6.5 mmol/l versus no difference between SPS and placebo control (null hypothesis).
Interventions
- DRUG Sodium polystyrene sulfonate
- DRUG Silicified microcrystalline cellulose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2013-05 |
| Est. Completion | 2013-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01866709
The ClinicalTrials.gov registry entry for NCT01866709 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ZS Pharma, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sodium polystyrene sulfonate is the first listed.
NCT01866709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01866709 about?
NCT01866709 is a clinical study titled "Safety and Efficacy of Sodium Polystyrene Sulfonate in Hyperkalemia". It is hypothesized that SPS is more effective than placebo control (alternative hypothesis) in lowering i-STAT potassium levels in subjects with i-STAT potassium levels between 5.0 - 6.5 mmol/l versus no difference between SPS and placebo control (null hypothesis).
What is the current status of trial NCT01866709?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2013-05. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01866709?
The interventions under investigation include: Sodium polystyrene sulfonate (DRUG), Silicified microcrystalline cellulose (DRUG).
Who is sponsoring clinical trial NCT01866709?
This trial is sponsored by ZS Pharma, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.